The findings and conclusions in these presentations have not been formally disseminated by the Centers for Disease Control and Prevention and should not be construed to represent any agency determination or policy.

Northwest 2
Tuesday, March 11, 2008: 10:00 AM-11:45 AM

A7: Monitoring the Impact of the Human Papillomavirus (HPV) Vaccine: The National Perspective

Organizers:Susan Hariri
S. Deblina Datta
Moderator:Lauri Markowitz
 
Summary: Background/Purpose:

HPV is a sexually transmitted infection and the primary cause of genital warts and anogenital cancers. A new prophylactic HPV vaccine is recommended for routine use in females ages 11-12 years with catch-up for 13-26 year olds. Evaluating the impact of the vaccine requires monitoring several biologic and behavioral endpoints.

Objectives of Symposium:

Provide an overview of national efforts to develop sustainable systems to monitor the impact of HPV vaccine on disease outcomes and screening behaviors.

Implications for Programs, Policy, and/or Research:

Information presented will highlight national efforts toward a coordinated approach to HPV impact monitoring and the role of STD programs therein.

 
10:00 AM Introduction and Overview
Lauri E. Markowitz
10:05 AMA7aMonitoring Genital Warts in STD Clinics
Lori M. Newman
10:20 AMA7bMonitoring Cervical Precancer and Cancers HPV DNA Type Distribution using the National Program of Cancer Registries (NPCR)
S. Deblina Datta
10:35 AMA7cMonitoring Cervical Cancer Precursors, HPV Type Distribution, and Vaccination Status through the Emerging Infections Program Network
Susan Hariri
10:45 AMA7dUse of VSD to Monitor HPV-related Outcomes and HPV Types
Eileen F. Dunne
10:55 AMA7eEvaluating Vaccine Uptake and Safety Using Immunization Information Systems and VAERS
Diana L. Bartlett
11:05 AMA7fAssessing Vaccine Impact on Cervical Cancer Screening and Sexual Behaviors
Jasmin A. Tiro

The 2008 National STD Prevention Conference of CDC